Nonadherence to guidelines in the management of hepatocellular carcinoma: An Italian or universal phenomenon?

Future Oncology

Volumn 9, Issue 4, 2013, Pages 465-467

  Borzio, Mauro ^a   Sacco, Rodolfo ^b  

^a Azienda Ospedaliera di Melegnano   (Italy)

^b CISANELLO HOSPITAL   (Italy)

Author keywords

AASLD guidelines; field practice; hepatocellular carcinoma; Italy; liver cancer; management; sorafenib

Indexed keywords

AWARENESS; CANCER EPIDEMIOLOGY; CANCER STAGING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; HEALTH CARE ACCESS; HEALTH CARE FACILITY; HEALTH CARE PLANNING; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HIGH RISK PATIENT; HUMAN; ITALY; LIVER CELL CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PATIENT DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESOURCE ALLOCATION; REVIEW; ULTRASOUND;

CARCINOMA, HEPATOCELLULAR; FEMALE; GUIDELINE ADHERENCE; HUMANS; LIVER NEOPLASMS; MALE;

EID: 84875931347     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.29     Document Type: Review

References (13)

1. Grimshaw JM, Russell IT. Achieving health gain through clinical guidelines II: ensuring guidelines change medical practice. Qual. Health Care 3, 45-52 (1994).
2. Santi V, Buccione D, Di Micoli A, et al. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. J. Hepatol. 56, 397-405 (2012).
3. Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 52, 132-141 (2010).
4. Rosa I, Denis J, Renard P, et al. A French multicentric longitudinal descriptive study of hepatocellular carcinoma management (the CHANGH cohort): preliminary results. J. Hepatol. 53, S231-S232 (2010).
5. Borzio M, Fornari F, De Sio I, et al. Adherence to AASLD guidelines for the management of hepatocellular carcinoma: results of an Italian field-practice multicenter study. Future Oncol. 9(2), 283-294 (2013).
6. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 35, 421-430 (2001). (Pubitemid 32844200)
7. Bruix J, Sherman M; Practice Guidelines Committee; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 42, 1208-1236 (2005).
8. Bruix J, Sherman M. Management of hepatocellular carcinoma, an update. Hepatology 53, 1020-1022 (2011).
9. European Association For The Study of The Liver, European Organisation For Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908-943 (2012).
10. Vilana R, Forner A, Bianchi L, et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 51, 2020-2029 (2010).
11. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 19, 329 -338 (1999).
12. Song P, Tobe RG, Inagaki Y, et al. The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011. Liver Int. 32(7), 1053-1063 (2012).
13. Italian Association for the Study of Liver. [AISF recommendations for the integrated management of HCC patients (2012). www.webaisf.org/media/16110/ raccomandazioni-aisf-per-hcc.pdf